Essilor Stellest becomes the only US FDA market authorised spectacle lens for myopia control in India

Late last year, EssilorLuxottica announced the US Food and Drug Administration (FDA) granted market authorisation for its Essilor® Stellest® lens using the De Novo pathway.

This follows the product’s earlier recognition with the FDA granting designation as a Breakthrough Technology in 2021. The Essilor® Stellest® lens is the first and only US FDA market authorised spectacle lens to slow myopia progression in children.

The effectiveness of the Essilor® Stellest® lens is evidenced by clinical data showing that the lens slowed down myopia progression by 71% on average over two years. 

The sharp rise in myopia is a growing concern in India, with nearly 50% of urban children projected to be affected by 2050. With its legacy of clinical reliability, EssilorLuxottica aims to advance myopia care in India through FDA-approved innovations for slowing down of Myopia progression aligned with National Accreditation Board for Hospitals (NABH) & Healthcare Providers and global standards.

By empowering doctors, parents, and institutions with internationally recognized, evidence-based myopia management, the goal is to transform the standard of care by making Essilor® Stellest® accessible to more children across India.

As eye testing is not mandatory in India there are many children that go undetected or uncorrected and it’s important for parents to include eye testing as part of their routine back to school checks.

EssilorLuxottica is prioritising regions with high myopia awareness and early adoption potential, including Metro cities and emerging hubs like Pune, Coimbatore, Ahmedabad, Kochi, and Chandigarh.

The expansion will gradually extend to Tier-2 and Tier-3 cities through optical ophthalmologists, optometrists, and optical networks and professional education programmes.